Fagron Acquires University Compounding Pharmacy (UCP)

Fagron Completes Acquisition of University Compounding Pharmacy (UCP)

January 12, 2026

Pharmaceuticals

Fagron has completed the acquisition of University Compounding Pharmacy (UCP), a San Diego–based 503A compounding pharmacy focused on hormone and urology therapies. The transaction values UCP at approximately $41.5 million; UCP generates roughly $25 million of annual revenue. Fagron said the purchase supports its strategy to build a nationwide U.S. compounding platform (complementary to Anazao) and strengthens its presence in California.

Fagron Acquires Purifarma in Brazil

January 6, 2026

Pharmaceuticals

Fagron has completed the acquisition of Purifarma, a large-scale pharmaceutical essentials business in Brazil, for an enterprise value of approximately R$250 million. The deal strengthens Fagron's scale and procurement position in Latin America and supports the Group's buy-and-build strategy to expand its pharmaceutical compounding and essentials platform.

Eden Health Acquires Contigo Compounding

August 19, 2025

Healthcare Services

Eden Health has acquired Contigo Compounding, a licensed 503A compounding pharmacy, to integrate in-house sterile and non-sterile compounding capabilities into its personalized care platform. The acquisition gives Eden direct control of medication preparation and supply chain for faster adjustments, improved adherence, and next-day shipping for members.

Revelation Pharma Acquires Taylors Pharmacy and Key Compounding Pharmacy

July 9, 2024

Healthcare Services

Revelation Pharma, a national network of 503A and 503B compounding pharmacies, has acquired Taylors Pharmacy (Florida) and Key Compounding Pharmacy (Federal Way, Washington). The acquisitions expand Revelation's coast-to-coast footprint and bring both pharmacies into its compounding network as Revelation assumes full operations; the sellers are the founders/owners Allen Deaver and HeeJoo Park.

Revelation Pharma (Osceola Capital) Acquires Five Compounding Pharmacies

January 27, 2022

Healthcare Services

Revelation Pharma, a PE-backed specialty pharmacy platform sponsored by Osceola Capital, completed add-on acquisitions of five compounding pharmacies: Innovation Compounding, Pencol Compounding Pharmacy, Pharmacy Specialists Compounding, Wise Pharmacy, and Convex Pharmacy. The deals expand Revelation's geographic footprint and clinical capabilities across key U.S. regions and will see some locations merged into existing Revelation businesses (e.g., Wise into Pencol; Convex into Everwell).

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.